AddLife strengthens coagulation diagnostics portfolio with CoaChrom acquisition

The latest announcement is out from AddLife AB ( ($SE:ALIF.B) ).

AddLife AB has acquired CoaChrom Diagnostica GmbH, an Austrian specialist in advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry, with around EUR 10 million in sales and 10 employees. CoaChrom, known for its niche assays, reagents and long-standing relationships with leading hospitals and industrial customers, will be integrated into AddLife’s Labtech business area while retaining its brand and a high degree of operational independence.

The deal strengthens AddLife’s position in advanced coagulation diagnostics, broadens its offering to both clinical and pharmaceutical customers, and aligns with its strategy of building a portfolio of specialised life science businesses. Management expects the acquisition, which closed on 22 April 2026, to deliver a marginally positive effect on earnings per share this financial year, while giving CoaChrom access to AddLife’s broader platform, resources and international reach for accelerated product and market development.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK178.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.

More about AddLife AB

AddLife AB is a Stockholm-listed life science group that supplies high-quality products, services and advisory solutions to private and public healthcare and laboratory customers across Europe. Through about 85 subsidiaries and 2,300 employees, the company generates more than SEK 10 billion in annual net sales and operates with a decentralised business model focused on specialised niches.

Average Trading Volume: 178,302

Technical Sentiment Signal: Strong Buy

Current Market Cap: SEK20.49B

Find detailed analytics on ALIF.B stock on TipRanks’ Stock Analysis page.